

Adolescent Cancer Awareness: improving education and understanding of testicular cancer, melanoma and HPV-related cancers in adolescents

Michael Kiritsy¹, Tyler Mehegan¹, Jacqueline Pires¹, Michele Sainvil¹, Linda Fantasia², David Estabrook², Suzanne Cashman¹

¹ University of Massachusetts Medical School 55 Lake Avenue North, Worcester MA 01655

² Carlisle Board of Health 66 Westford Street, Carlisle, MA 01741

Introduction

Background:

- Evidence-based cancer screening tools have contributed to a decline in the number of new cancer cases and prevented deaths from some cancers.

Our goals:

- Empower young adults to become active participants in their health.
- Promote healthy habits early on to avoid development of cancer
- Discourage the use of tanning beds, obtain HPV vaccinations, self-examinations

Target Population

Town demographics:

- Population: 4,870
- 99.7% have a high school diploma
- Median Household income is \$160,000
- 97.3% have health insurance coverage
- 81.7% have BA degree or higher
- Carlisle has a very low unemployment rate
- Nearby towns: Concord, Acton, Westford, Bedford, Billerica, Chelmsford
- Strong History of community health promotion
- Concerns in Carlisle:
 - Carlisle is a small town with an inherently limiting sample size
 - Testicular cancer: 2 cases within recent year
 - Melanoma: statistically significant incidence in Carlisle per MCR incidence data 2005-2009

Goal & Process

Goals:

The goal of our project was to increase the awareness in Carlisle's adolescent population regarding cancer prevention, and behaviors that may put them at risk for the development of cancer later in life. The three cancers we chose were testicular cancer, with the goal of promoting self-examinations, melanoma, aiming at encouraging proper sun screen use and discouraging tanning bed use, and HPV-related cancers, in the hope of increasing vaccination in adolescent men and women.

Process:

For each of these cancers, we created an interactive online quiz which is linked to the 3 QR codes and to the concord Carlisle DPH website. These quizzes are geared towards increasing awareness of these three cancer topics, and promoting preventative and early detection behaviors

Acknowledgments

Carlisle: Linda Fantasia; David Eastbrook; Board of Health
UMMS: Suzanne Cashman, Diane Blake, MD
Lahey Clinic: Jason Gee, MD
Dana Farber Cancer Institute: MacDonald, Bruce F.,L.I.C.S.W.
Harvard Vanguard/Concord Hillside: Ronni Goldsmith, MD
Concord-Carlisle High School: Christine DeBruzz, RN
Melanoma Foundation of New England: Deb Gerard

Testicular Cancer

What you need to know about Testicular Cancer (TC):

- USA has 5th highest TC age-standardized incidence rate
 - 5.2 out of 100,000 men diagnosed with TC annually
 - Incidence of testicular cancer has been rising globally
- TC incidence increasing, yet mortality decreasing (past 30 years)
- Increase in 5-year survival rates from 63% to greater than 90%
- 98% of TC are of germ cell origin

Risk factors:

- Cryptorchidism (undescended/abnormal testicular development)
- Family history of germ cell tumors: 4-10-fold increased risk of TC
- Race: White men 5x more likely than AA or Asian to develop TC
- Age: 15-40 are at higher risk

Treatment:


- TC diagnosis, regardless of stage, has excellent prognosis with treatment
- More than 95% of all men diagnosed with TC survive after treatment
- Earlier detection equals a better prognosis and decreases complications



Melanoma

What you need to know about melanoma:

- Two-thirds of melanoma may be attributed to UV exposure
- Tanning Beds:**
 - Ever used in lifetime → 20% increase in risk for melanoma
 - First use in teens/20s → 75% increased risk for melanoma
 - American Academy of Pediatrics supports ban: children < 18yrs
 - Addiction process similar to opiate abuse



Sun Screen:

- 73% risk reduction for those who follow sunscreen guidelines
- National Council on Skin Cancer Prevention recommendations:
 - SPF of at least 30
 - Re-apply every 2 hours whether swimming or not
 - Sunscreen labeled "Broad Spectrum" for both UVA and UVB rays

HPV-related Cancers

What you need about the HPV-vaccine:

- About 79 million Americans are HPV-infected
- 14 million Americans are infected each year
- Only 39.3% of Massachusetts adolescent females aged 13-17 receive the complete 3-dose HPV series; only 37.6% nationally
- Male vaccination rates are only 14% nationally
- Current Recommendations:**
 - The HPV vaccine is CDC-recommended for both males and females at 11-12 years of age
 - Surveys show that the HPV vaccine does not cause anymore pain than other common vaccinations
 - The HPV vaccine protects against HPV infection and is only effective if given before exposure (ages 11-12).
 - The HPV vaccine lowers cancer risk for many cancers that are HPV-16 and HPV-18 related including cervical, anal, vaginal, vulvar, penile and oropharyngeal cancers
 - The HPV vaccine has not been shown to promote promiscuity



Common Parental Questions

- Will insurance pay for the vaccine?
 - Most insurances cover the HPV vaccine
- What if my child is not covered?
 - The Vaccines for Children (VFC) program can help provide access to the HPV vaccine for children who may not otherwise be able to have access to it

Conclusions and Future Directions

What we accomplished?

- Created awareness materials based on target population needs
- Bridged the ideas of interprofessional teams in order to achieve holistic end-product for adolescents
- Used proper venues & marketing tools to attract intended audience
- Gained insight on our role as future physicians regarding the promotion of healthy living habits

Future Directions

- Obtain survey responses to further assess target population's health-related knowledge
- Increase circulation of awareness materials for adolescents outside of Carlisle

References

Armstrong BK, Kiritsy A. How much melanoma is caused by sun exposure? *Melanoma Res* 1993; 3:395.
Baird A, Ro JV, Ayala AG. An overview of testicular germ cell tumors. *Arch Pathol Lab Med* 2007;131(8):1267-1280.
Behavioral Risk Factor Surveillance System (BRFSS)
Belinfante, A. (February 2010). Telephone subscription in the United States: Data from November 2009. Federal Communications Commission. Retrieved on October 28, 2010. <http://www.fcc.gov/encyclopedia/telephone-subscription-in-the-united-states-data-from-november-2009>
Bren P, Richard L, Ekbom A, Pukkala E, Cukler M, Moller H. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. *Int J Cancer* 2006;119(12):3099-3111.
Goldsmith L, Koch HK, Bewers J, et al. Proceedings of the national conference to develop a national skin cancer agenda. *American Academy of Dermatology and Centers for Disease Control and Prevention* 2007;109(10):926-929.
Greene MR, Kratz CP, Mai PL, et al. Familial testicular germ cell tumors in adults: 2010 summary of genetic risk factors and clinical phenotype. *Endocr Relat Cancer* 2010;17(2):R109-R121.
Harrington CR, Bewick TC, Leitnerberger J, et al. Addictive-like behavior after ultraviolet light exposure in tanners. *Clin Exp Dermatol* 2011; 36:33.
HPV Vaccine as a Preventive Health Priority. *August 2014. <http://www.cdc.gov/acip/2014/08/08/140821-hpv-vaccine-as-a-preventive-health-priority.pdf>*
HPV Vaccination for Women. *Centers for Disease Control and Prevention. <http://www.cdc.gov/std/hpv/std-and-cancer/hpv-vaccination-for-women-fact-sheet.pdf>*
International Agency for Research on Cancer Working Group on artificial ultraviolet (UV) light and skin cancer. The association of use of sunbeds with cutaneous malignant melanoma and other skin cancers: A systematic review. *Int J Cancer* 2007; 120:1113.
Kao M, Chang A, Wang J, et al. A randomized, double-blind, placebo-controlled trial of topical 5-fluorouracil versus placebo in the treatment of actinic keratoses in a small randomized, controlled trial of topical 5-fluorouracil in frequent tanners. *J Am Acad Dermatol* 2006; 54:709.
Kraus C, Loosli LH. Genetic aspects of testicular germ cell tumors. *Crit Rev Oncol Hematol* 2008; 71(2):3519-3524.10.1016/j.critrevonc.2007.12.002.
Krieger DM, Sonis SB, Ottesen AM, et al. Origin of pluripotent germ cell tumors: the role of microenvironment during embryonic development. *Mol Cell Endocrinol* 2006;288(1-2):111-118.
Literature review to identify risk factors
Massachusetts Cancer Registry (MCR) city-and-town reports
Massachusetts Department of Environment. *Statewide Environmental Health Assessment and Monitoring Program (SEAMP) data*
Massachusetts Department of Public Health. Bureau of Health Information, Statistics, Research and Evaluation. *MasCHIP*. Available at: <http://www.mass.gov/dph/maschip>
Massachusetts Environmental Public Health Tracking (MA EPHT) data
National Center for Health Statistics. *Statistical Briefs*. (January 13, 2010). Reliability of Survey Estimates. Retrieved October 28, 2010, from <http://www.cdc.gov/nchs/about/ahc/reliability.htm>
F1000Research 2013;3:25. <https://doi.org/10.1260/f1000research.23513>
Moser CE, Danoff-Burg S. Addiction to indoor tanning: relation to anxiety, depression, and social support. *Arch Dermatol* 2010; 146:412.
National Institute for Skin Cancer Prevention. *Prevention*. Accessed on January 25, 2007.
Shannagh RM, Saito S, Saito S, et al. Global incidence and outcome of testicular cancer. *Clin Epidemiol* 2013;5:417-427.
Shannagh RM, Saito S, Saito S, et al. Global incidence and outcome of testicular cancer. *Clin Epidemiol* 2013;5:417-427.
Sakamoto T, Ropponen K, Mehta MM. Testicular dysgenesis syndrome and its incidence in common developmental disorders. *Hum Reprod* 2001;16(5):972-978.
The HPV Vaccine: Access and Use. *July 13, 2014. <http://www.cdc.gov/std/hpv/news-updates/july-2012.html>*
The Office of Adolescent Health, U.S. Department of Health and Human Services. *July 13, 2014. <http://www.hrsa.gov/ahc/act-sheet/the-hpv-vaccine-access-and-use-inf>*
The Office of Adolescent Health, U.S. Department of Health and Human Services. *July 13, 2014. <http://www.hrsa.gov/ahc/news-updates/july-2012.html>*
Youth Risk Behavior Survey (YRBS)

For additional information, please contact: michael.kiritsy@umassmed.edu

